Category — Pharmaceuticals
Emcure Pharmaceuticals, a drug maker based in Pune in the western state of Maharashtra, has acquired Canada‘s International Pharmaceutical Generics Ltd. and its marketing arm Marcan Pharmaceuticals. Marcan Pharma has over 60 approved products mainly available from McKesson and Kohl & Frisch, among other wholesalers, reports Economic Times.
Emcure recently estimated its annual global sales at over $670 million having widened its base from contract manufacturing. The company has a strong presence in India, U.S., and European markets.
Emcure’s entry into Canada is similar to the strategy it had adopted during the acquisition of U.S.-based Heritage Pharmaceuticals in 2011. Emcure’s support to Heritage accelerated its U.S. sales for FY 2016 to $265 million. Industry experts say that Canada could be attractive for Emcure, although there could be challenges as the Canadian government implements a reference pricing system.
January 31, 2016 No Comments
According to a report in Live Mint which quoted data from VCCEdge, outbound mergers and acquisitions in the healthcare sector in India were worth $1.5 billion in 2015 as against $251 million in 2014.
|Lupin, India||Gavis Pharmaceuticals, U.S.||$880 million|
|Cipla, India||InvaGen and Exelan, U.S.||$550 million|
|Strides Arcolab, India||Aspen Pharmacare, Australia||$287 million|
Inbound deals also more than doubled to $999 million in 2015 from $430 million in 2014.
|Mylan, U.S.||Famy-Care, India||$800 million|
|Recipharm AB, Sweden||Nitin Life Sciences, India||$100 million|
|IHH Healthcare Bhd, Malaysia||Ravindranath GE Medical, India||$200 million|
|IHH Healthcare Bhd, Malaysia||Continental Hospitals, India||$45.4 million|
|Temasek Holdings, Singapore||Medanta, India (18% stake)||undisclosed|
|Bionpharma, U.S.||Banner Life Sciences, India (25 products that generate $70 million annually)||undisclosed|
January 30, 2016 No Comments
Novartis Group inaugurated its new business center, Novartis Knowledge City, in Hyderabad, India. A nine-storied structure with a gross area of 800,000 square feet, this facility is the largest of the group’s five global service centers, located in Mexico City, Dublin, Prague, Kuala Lumpur.
The Novartis Business Services in Hyderabad currently has 3,500 employees, and provides services in IT, financial reporting and accounting, human resources services, procurement and product lifecycle services. Pharma development focuses on data management, statistics, regulatory affairs, pharmacovigilence and clinical trial operations, reports Yahoo News.
December 23, 2015 No Comments
Purdue University has signed a memorandum of understanding with Dr. Reddy’s Laboratories Limited, Hyderabad, India, to strengthen pharmaceutical research and development. The intent is to forge a strong strategic partnership in a range of research areas and novel technologies. Areas of planned collaborative research and education include targeted drug delivery, manufacturing technology, scale-up of pharmaceutical operations, process engineering, and research and development methodologies and technology. The collaboration will include student engagement and faculty exchanges and may include a site at Purdue Research Park.
“Purdue has tremendous strength in pharmaceutical drug discovery and development research, but we need additional partners to help translate our discoveries through to the delivery of a medicine or technology,” Suresh Garimella, Purdue executive vice president for research and partnerships, said. “Dr. Reddy’s Laboratories is a global pharmaceutical company that shares our mission to accelerate the rate at which new, advanced treatments make it to the millions of patients in need of relief. This partnership combines strengths that could lead to world-changing research.”
December 4, 2015 No Comments
Plandai Biotechnology Inc., based in Utah, has concluded a deal with Bangalore-based Bal Pharma for the distribution of its ingredients in India. Bal Pharma, which manufactures and exports pharmaceutical finished drugs and distributes nutraceutical constituents, will use Plandai’s Phytofare line of plant extracts in its own products and will also market them as active ingredients in India says Nutraingredients-usa.com.
“Bal Pharma should quickly be able to generate substantial market penetration for Plandai. Our agreement with such a highly-regarded Indian company further validates the fifteen years of research that has gone into bringing Phytofare to market and the solid science behind our phyto-available products,” said Callum Cottrell-Duffield vice president for sales for Plandai.
November 27, 2015 No Comments